Loqtorzi Side Effects

Generic name: toripalimab

Medically reviewed by Drugs.com. Last updated on Mar 10, 2025.

Note: This document provides detailed information about Loqtorzi.

Applies to toripalimab: parenteral solution for injection Side Effects associated with toripalimab. Some dosage forms listed on this page may not apply specifically to the brand name Loqtorzi.

Applies to toripalimab: parenteral solution for injection.

Side effects include:

Most common adverse reactions (≥20%) with toripalimab-tpzi in combination with cisplatin and gemcitabine: nausea, vomiting, decreased appetite, constipation, hypothyroidism, rash, pyrexia, diarrhea, peripheral neuropathy, cough, musculoskeletal pain, upper respiratory infection, insomnia, dizziness, malaise.

Most common adverse reactions (≥20%) with toripalimab-tpzi as single agent: fatigue, hypothyroidism, musculoskeletal pain.

For healthcare professionals

Applies to toripalimab: intravenous solution.

General adverse events

The most common adverse reactions of 20% or greater frequency were nausea, vomiting, decreased appetite, constipation, hypothyroidism, rash, pyrexia, diarrhea, peripheral neuropathy, cough, musculoskeletal pain, upper respiratory infection, insomnia, fatigue, dizziness, and malaise.

Cardiovascular

• Common (1% to 10%): Hypertension
• Frequency not reported: Myocarditis, pericarditis, pericardial effusion, vasculitis^[Ref]

Hypertension included blood pressure increased, blood pressure systolic increased, hypertension, and hypertensive crisis.^[Ref]

Dermatologic

• Very common (10% or more): Rash (up to 36%), pruritus (up to 17%)

Rash included acneiform dermatitis, allergic dermatitis, catheter-site rash, dermatitis, drug eruption, eczema, erythema, macule, maculopapular rash, palmar-plantar erythrodysesthesia syndrome, papule, pruritic rash, rash, and urticaria.

Endocrine

• Very common (10% or more): Hypothyroidism (up to 38%)
• Frequency not reported: Hypoparathyroidism

Hypothyroidism included hypothyroidism, tri-iodothyronine decreased, tri-iodothyronine free decreased, and thyroiditis.

Gastrointestinal

• Very common (10% or more): Nausea (up to 71%), vomiting (up to 68%), constipation (up to 39%), diarrhea (up to 31%), stomatitis (up to 12%)
• Frequency not reported: Duodenitis, gastritis, pancreatitis

Stomatitis included mouth ulceration, stomatitis, and radiation stomatitis. Pancreatitis included increases in serum amylase and lipase levels.

Hematologic

• Very common (10% or more): Decreased hemoglobin (up to 94%), decreased neutrophils (up to 91%), decreased lymphocytes (up to 88%), decreased platelets (up to 71%)
• Common (1% to 10%): Epistaxis
• Frequency not reported: Hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis, systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenic purpura, solid organ transplant rejection

Metabolic

• Very common (10% or more): Decreased magnesium (up to 78%), decreased sodium (up to 63%), increased ALT (up to 58%), increased AST (up to 58%), decreased appetite (up to 55%), decreased albumin (up to 49%), decreased calcium (up to 45%), increased LDH (up to 42%), increased calcium (up to 39%), decreased potassium (up to 40%), increased creatinine (up to 39%), increased alkaline phosphatase (up to 27%), increased triglyceride (26%), decreased glucose (up to 23%), decreased weight (11%)

Musculoskeletal

• Very common (10% or more): Musculoskeletal pain (up to 25%)
• Frequency not reported: Myositis/polymyositis, rhabdomyolysis (and associated sequelae, including renal failure), arthritis, polymyalgia rheumatica, dermatomyositis

Musculoskeletal pain included back pain, bone pain, musculoskeletal chest pain, musculoskeletal pain, myalgia, neck pain, pain in extremity, pain in jaw.

Nervous system

• Very common (10% or more): Peripheral neuropathy (up to 30%), dizziness (up to 21%), headache (up to 18%)
• Frequency not reported: Meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis (including exacerbation), Guillain-Barré syndrome, nerve paresis, autoimmune neuropathy

Peripheral neuropathy includes hypoesthesia, neuralgia, neuropathy peripheral, paresthesia, peripheral sensory neuropathy.

Other

• Very common (10% or more): Pyrexia (up to 32%), malaise (up to 21%), fatigue (up to 19%; includes asthenia and fatigue)

Fatigue included asthenia and fatigue.

Psychiatric

• Very common (10% or more): Insomnia (up to 23%)

Respiratory

• Very common (10% or more): Cough (up to 26%), upper respiratory infection (up to 23%), pneumonia (up to 18%)

Cough included cough and productive cough. Upper respiratory infection included acute sinusitis, bronchitis, laryngitis, nasopharyngitis, pharyngitis, respiratory tract infection, rhinitis, sinusitis, and upper respiratory tract infection. Pneumonia included aspiration pneumonia and pneumonia.

Frequently asked questions

• What are monoclonal antibodies?
• What is the MOA of Loqtorzi (toripalimab)?
• How does Loqtorzi work for nasopharyngeal carcinoma?
• How Accurate is Screening for Nasopharyngeal Carcinoma?

Further information

Loqtorzi side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer